Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    pipeline-prospector-insert-v1
    X

    Find Drugs for Sleep in Phase II Clinical Development

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type

              Companies

              Pfizer Inc

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Contact Supplier Contact Supplier

              Virtual Booth Virtual Booth

              Immuno-Oncology 360

              Participation Not Confirmed

              Update your events

              Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data an...

              Contact the Supplier

              Lead Product(s): Reboxetine

              Therapeutic Area: Sleep

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Axsome Therapeutics

              Deal Size: $331.0 million Upfront Cash: $3.0 million

              Deal Type: Licensing Agreement January 13, 2020

              Details:

              Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy which xpands Axsome’s pipeline with new Phase 3-stageesreboxetine product candidate for fibromyalgia

              Adare Pharmaceuticals

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Immuno-Oncology 360

              Participation Not Confirmed

              Update your events

              Adare Pharmaceuticals and NLS Pharmaceutics Collaborate to Develop Mazindol Controlled Release (CR) for the Treatment of ADHD and Narcolepsy

              Contact the Supplier

              Lead Product(s): Mazindol

              Therapeutic Area: Sleep

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: NLS Pharmaceutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 13, 2020

              Details:

              NLS Pharmaceutics entered a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and ADHD utilizing Adare’s proprietary modified release technologies.

              PharmaCompass__DigitalAd